Felipe J. S. Jones

June is #MyastheniaGravis Awareness Month. #MG is a rare autoimmune neuromuscular disease that causes fluctuating muscle weakness and fatigue. TSF stands with the MG community - learn, share, amplify patient voices, support advocacy and make invisible symptoms visible. 💙

Final reflection for today: the essence of professionalism is to know what you are doing, and to care about the effect of everything you do.

MAJOR news for the #MG community 🚨 The FDA has expanded approval for VYVGART + VYVGART Hytrulo to all adults with generalized #myastheniagravis, including MuSK+, LRP4+ and seronegative patients. More access. More recognition. More hope argenx.com/news/2026/pres…

Chicken or egg in neurodegeneration ? In IgLON5 disease, the answer is becoming clear: autoantibodies initiate the cascade, tau comes later. In our @Brain1878 editorial, we explore how this reshapes timing, diagnosis, and treatment. @Mayo_AING academic.oup.com/brain/article/…

Happy to share @NisaVorasoot et al study of demographics & seasonality of 10K MOG & AQP4 IgG (+) showing females predominate in #MOGAD (1.5:1) and #NMOSD (6.2:1) & a pediatric predilection of #MOGAD with onset & attacks of both slightly higher in winter👇neurology.org/doi/10.1212/WN…

Happy to share @andreuvilaseca7 et al collaboration with @ESotirchos on the TRUE-MOGAD Score to discriminate true & false positive MOG-IgG ➡️ We have created an online calculator for ease of use: news.mayocliniclabs.com/true-mogad-cal… The article link is below: 👇 neurology.org/doi/10.1212/NX…

Excited to share our study in @NatureComms. Immunosignatures decode tumor–immune interactions in testicular cancer, extrapolating beyond paraneoplastic autoimmunity. 93% sensitivity, 99% specificity, including biomarker-negative cases. #CancerImmunology nature.com/articles/s4146…

Many leaders in medicine are focused on AI and how it’s going to solve problems in medicine. Maybe. But doctors with great clinical acumen, empathy, and the wisdom to make the right judgment call are the ones we need more of, and who patients want and seek out. This is the important stuff.

Excited to share our phase 3 trial published today in The New England Journal of Medicine evaluating brepocitinib in dermatomyositis. In this randomized, placebo-controlled study—the largest myositis trial to date—brepocitinib 30 mg daily led to significant improvements across a validated composite myositis outcome measure, including skin disease activity, glucocorticoid tapering, and physical function. Three key takeaways: ⚡ Rapid onset of efficacy, with improvements observed as early as week 4 ⏳ Durable response through 52 weeks 🎯 Targeted mechanism modulating the IFN pathway—a central driver of disease—with meaningful steroid-sparing effects These findings support a shift toward more targeted, mechanism-based therapies in dermatomyositis. Grateful to have contributed as a co-first and co-corresponding author to the design and execution of this study, and to the patients and investigators across participating sites who made this work possible. nejm.org/doi/full/10.10…

Meu livro está disponível em versão impressa! Escrito , e publicado digitalmente em 2020 ( antes das LLMs, loja.uiclap.com/titulo/ua15735… ). Medidas e dispersão, Distribuição Gaussiana, Regressão, Modelos multivariados, DAGs, Inferência Bayesiana e Redes Neurais. Confiram!

We are actively recruiting for the SUMMIT Trial (Study of Ublituximab in Immune-Mediated Necrotizing Myopathy), an NIH-funded, multi-center Phase 2 clinical trial in immune-mediated necrotizing myopathy (IMNM). I serve as the Principal Investigator and Protocol Chair of this NIH UM1-funded study, which is designed to advance mechanism-informed treatment strategies for patients with IMNM. We are currently enrolling patients with: • Anti-SRP or Anti-HMGCR positive IMNM • Disease duration ≤ 12 months The SUMMIT Trial is being conducted across a national multi-center network through the @NIAIDNews National Institute of Allergy and Infectious Diseases (NIAID)Autoimmunity Centers of Excellence, with the goal of improving outcomes and establishing a foundation for next-generation IMNM clinical trials. If you are a clinician caring for newly diagnosed IMNM patients, or would like information about participating sites- referrals and inquiries are welcome. 📩 Study contact: summit.IMNM.trial@gmail.com #Myositis #IMNM #ClinicalTrials #RareDisease #AutoimmuneDisease

They take care of the sickest patients. They’re at the bedside on weekends. On holidays. In the middle of the night. They are the altruistic, diligent, compassionate, and creative engine of our academic healthcare mission. Whether we know it or not, we have all benefited from their care. Today is Thank a Resident Day. If you see a resident or fellow today, please thank them. (It’s OK to thank them the rest of the year too.) If there’s a trainee or group you want to call out in particular, drop it in the replies!

Dear Neuromuscular Medicine Fellowship Applicants: Apply to our program! Master EMGs, NM ultrasound, and nerve and muscle biopsy interpretation through clinical rotations, elite didactics, and 3 months of electives. We look forward to interviewing and getting to know you!

IgLON5 in 10 years: from disease discovery to mechanism🤯 This study in @Brain1878 suggests that even IgG4 anti-IgLON5 may come before “typical” tau, nuclear pSer422-tau is already detectable, with nuclear abnormalities reproduced by adding IgLON5 Abs to neurons in vitro!

“Science is fundamentally different than, say, remodeling a kitchen.” A must-listen interview by former NIH Deputy Director for Extramural Research on the history of federal funding, pitfalls of the process and suggested future of scientific research. statecraft.pub/p/whats-wrong-…

The importance of stupidity in scientific research journals.biologists.com/jcs/article/12…

This review examines some of the monogenic disorders that can masquerade as neuroinflammatory phenotypes: hubs.la/Q03WVsG10 #NeuroTwitter #NeuroX

Come join us in Half Moon Bay this spring! @MayoClinicNeuro @mayoneurores

@PulmCrit (1/n) Hi Josh, loved the trial and podcast episode on it. Not sure if I agree with your take on the mortality diff. A 1% point difference between arms is highly subjective to random noise... (I will post the Bayesian results at the end of this thread)